About: Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Alum Induces Protective Immunity and Reduces Immune Enhancement

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Alum Induces Protective Immunity and Reduces Immune Enhancement Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Alum Induces Protective Immunity and Reduces Immune Enhancement
Creator	Du, Lanying Peng, Bi-Hung Lustigman, Sara Algaissi, Abdullah Tao, Xinrong Agrawal, Anurodh Chen, Wen-Hsiang Strych, Ulrich Tseng, Chien-Te Bottazzi, Maria Edu, Plaza, Baylor Ab, Pollet Hotez Abef, Peter
Source	BioRxiv; Medline; PMC
abstract	We developed a severe acute respiratory syndrome (SARS) subunit recombinant protein vaccine candidate based on a highyielding, yeast- engineered, receptor-binding domain (RBD219-N1) of the SARS beta-coronavirus (SARS-CoV) spike (S) protein. When formulated with Alhydrogel®, RBD219-N1 induced high-level neutralizing antibodies against both pseudotyped virus and a clinical (mouse-adapted) isolate of SARS-CoV. Here, we report that mice immunized with RBD219N1/Alhydrogel® were fully protected from lethal SARS-CoV challenge (0% mortality), compared to ~ 30% mortality in mice when immunized with the SARS S protein formulated with Alhydrogel®, and 100% mortality in negative controls. An RBD219-N1 formulation Alhydrogel® was also superior to the S protein, unadjuvanted RBD, and AddaVax (MF59-like adjuvant)-formulated RBD in inducing specific antibodies and preventing cellular infiltrates in the lungs upon SARS-CoV challenge. Specifically, a formulation with a 1:25 ratio of RBD219-N1 to Alhydrogel® provided high neutralizing antibody titers, 100% protection with non-detectable viral loads with minimal or no eosinophilic pulmonary infiltrates. As a result, this vaccine formulation is under consideration for further development against SARS-CoV and other emerging and re-emerging beta-CoVs such as SARS-CoV-2.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1101/2020.05.15.098079
bibo:pmid	32511385
has license	cc-by-nc-nd
sha1sum (hex)	d4913d6e6ae6916d4f1c4157b6850a01574bd3a6
schema:url	https://doi.org/10.1101/2020.05.15.098079
resource representing a document's title	Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Alum Induces Protective Immunity and Reduces Immune Enhancement
has PubMed Central identifier	PMC7263514
has PubMed identifier	32511385
schema:publication	bioRxiv
resource representing a document's body	covid:d4913d6e6ae6916d4f1c4157b6850a01574bd3a6#body_text
is schema:about of	named entity 'emerging' named entity 'immunized' named entity 'RBD' named entity 'protein' named entity 'protein' named entity 'neutralizing antibodies' named entity 'pulmonary' named entity 'Immunity' named entity 'Aluminum' named entity 'ratio' named entity 'SARS-CoV' named entity 'mice' named entity 'recombinant protein' named entity 'emerging' named entity 'specific' named entity 'SARS-CoV-2' named entity 'subunit' named entity 'result' named entity 'consideration' named entity 'immunized' named entity 'SARS' named entity 'RBD' named entity 'SARS-CoV-2' named entity 'spike (S) protein' named entity 'vaccine' named entity 'RBD' named entity 'SARS-CoV' named entity 'mice' named entity 'coronavirus' named entity 'Alhydrogel' named entity 'pseudotyped' named entity 'protein' named entity 'SARS-CoV' named entity 'Alhydrogel' named entity 'yeast' named entity 'SARS-CoV' named entity 'Yeast' named entity 'Aluminum Hydroxide' named entity 'RBD' named entity 'mice' named entity 'RBD' named entity 'virus' named entity 'RBD' named entity 'protein' named entity 'Coronaviridae' named entity 'Alhydrogel' named entity '8,000' named entity 'lung' named entity 'SARS-CoV' named entity 'LD50' named entity 'virus' named entity 'mice' named entity 'fatality rate' named entity 'protein' named entity 'alum' named entity 'vaccine' named entity 'dose-ranging study' named entity 'Th17' named entity 'antibody response' named entity 'immunization' named entity 'Alhydrogel' named entity 'adjuvanted' named entity 'P. pastoris' named entity 'immunization' named entity 'neutralizing antibody' named entity 'MERS-CoV' named entity 'Alhydrogel' named entity 'Alhydrogel'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software